Cardiometabolic & kidneyTrial design
Design, rationale, and baseline characteristics of the dapagliflozin in haemodialysis (Dapagliflozin in Hemodialysis (DAPA-HD)) trial
- academic, multicentre, randomized, double-blind, placebo-controlled trial
- Stratified block randomization was based on patient-reported residual urine volume
Study context
- Population
- Patients with kidney failure receiving haemodialysisplanned enrolment
- Participants
- 220 patients
- Planned comparison
- Dapagliflozin vs placebo
- Primary endpoint
- Change in left ventricular mass indexed to body surface area using echocardiography
- Follow-up
- After 6 months of treatment
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Design, rationale, and baseline characteristics of the dapagliflozin in haemodialysis (DAPA-HD) trial. ESC Heart Fail. Published 9 April 2026. doi:10.1093/eschf/xvag104
Summarised from the published abstract; every number is checked against it